Revumenib

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Targeting menin dependency in acute leukemias: the role of revumenib in NPM1-mutated and KMT2A/NUP98-rearranged disease.

Targeting menin dependency in acute leukemias: the role of revumenib in NPM1-mutated and KMT2A/NUP98-rearranged disease.

Journal: Future oncology (London, England)

Published: October 29, 2026

Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia.

Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia.

Journal: Expert review of hematology

Published: September 13, 2026

Menin inhibition impairs metastatic colonization of Ewing sarcoma.

Menin inhibition impairs metastatic colonization of Ewing sarcoma.

Journal: JCI insight

Published: September 03, 2026

Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation.

Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation.

Journal: Molecular and cellular pediatrics

Published: August 24, 2026

Menin Inhibitors in Acute Myeloid Leukemia: From Molecular Rationale to Clinical Practice.

Menin Inhibitors in Acute Myeloid Leukemia: From Molecular Rationale to Clinical Practice.

Journal: Journal of personalized medicine

Published: August 18, 2026

Menin inhibition with revumenib clears measurable residual disease in acute myeloid leukemia with UBTF tandem duplication after allogeneic stem cell transplantation.

Menin inhibition with revumenib clears measurable residual disease in acute myeloid leukemia with UBTF tandem duplication after allogeneic stem cell transplantation.

Journal: Haematologica

Published: August 03, 2026

Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy.

Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy.

Journal: Cancers

Published: July 29, 2026

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2026

Menin Inhibitors in Acute Myeloid Leukaemia: Mechanisms, Clinical Pharmacology, and Emerging Therapeutic Strategies.

Menin Inhibitors in Acute Myeloid Leukaemia: Mechanisms, Clinical Pharmacology, and Emerging Therapeutic Strategies.

Journal: Critical reviews in oncology/hematology

Published: July 16, 2026

Oral Regimens for AML Make Strides.

Oral Regimens for AML Make Strides.

Journal: Cancer discovery

Published: June 27, 2026

Revumenib-Induced QTc Prolongation Leading to Multiple Episodes of Torsades de Pointes and Ventricular Arrhythmias.

Revumenib-Induced QTc Prolongation Leading to Multiple Episodes of Torsades de Pointes and Ventricular Arrhythmias.

Journal: Ochsner journal

Published: June 18, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Showing 1-12 of 114

Last Updated: 11/08/2026